Accurate and ultrasensitive detection of phosphorylated tau at threonine 231 (P-tau231), a pathologically validated early biomarker of Alzheimer's disease (AD), is essential for preclinical diagnosis and longitudinal monitoring. However, blood-based detection remains challenging because of the femtomolar physiological abundance, substantial interference from the serum matrix, and the reliance of conventional clustered regularly interspaced short palindromic repeats (CRISPR) assays on nucleic acid amplification. Herein, we present an amplification-free CRISPR/Cas12a-assisted surface-enhanced Raman scattering (SERS) aptasensor for the background-free quantification of P-tau231. This platform integrates aptamer-mediated target recognition, programmable Cas12a trans-cleavage-based signal transduction, and hierarchical plasmonic enhancement. Au-4-Mercaptobenzonitrile@Au (Au-4-MBN@Au) core-shell nanoprobes coupled with Ag nanocube arrays provide uniform plasmonic enhancement, while the characteristic C ≡ N peak of the 4-MBN reporter at 2230 cm-1 lies within the biological Raman-silent window (1800-2800 cm-1), thereby minimizing inference from endogenous scattering. This biosensor exhibits a linear detection range of 50 fg/mL to 5 ng/mL and an ultralow limit of detection of 2.53 fg/mL. Overall, this work established an effective amplification-free CRISPR/Cas12a-SERS platform for the highly sensitive detection of serum P-tau231 and offers a promising analytical approach for the blood-based early diagnosis of AD.